Navigation Links
CCHR Says New Mental Health Study on College Age Students Misleading
Date:12/24/2008

son & Johnson reported paying him $58,169 in 2001. Additionally, Biederman's colleagues at Harvard, Timothy E. Wilens and Thomas Spencer, failed to report $1.6 million and $1 million they earned from pharmaceutical drug companies, respectively. The consulting arrangements with drug makers were already controversial because of the researchers' advocacy of unapproved uses of psychiatric drugs in children.

More recently, according to the Boston Globe, Biederman emerged as a key witness in a huge, multistate lawsuit brought on behalf of more than 2,000 patients, including children, who claim to have been injured by psychiatric drugs known as atypical antipsychotics, including the Johnson & Johnson drug Risperdal, also known as "risperidone." A November 25 Boston Globe article, "Papers Reveal Push on Drug Firm Funds: Prominent Doctor Tied to Efforts," revealed that Biderman courted drug company money by promising that his work at Massachusetts General Hospital would help promote the use of antipsychotic drugs for youngsters diagnosed with bipolar disorder. Although Biederman's case highlights the extent of possible bias that shapes the psychiatric industry, it's not the first time drug corporations have been implicated behind the expanding psychiatric drug market

The July/August 2002 issue of Mother Jones included an article entitled "Disorders Made to Order," exposing the hidden influence behind psychiatric disorders marketed to the public. Barbara Mintzes, an epidemiologist at the University of British Columbia's Center for Health Services and Policy Research, said, "you oft
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Mutations common to cancer and developmental disorder examined in a novel disease model
2. National rates of co-occurring substance use and mental disorders call for better service integration
3. Celebrity Mental Health Musings Take Center Stage as Psych Central Adds New Blog
4. Benefits of Breastfeeding Outweigh Risk of Infant Exposure to Environmental Chemicals in Breastmilk
5. Latino Psychologist Appointed to Mental Health Post in Commonwealth
6. Mental Health America Celebrates 100 Years of Mental Health Advocacy and Support
7. Experimental Weight-Loss Pill Passes Early Test
8. Scientists, Physicians, Health, and Environmental Justice Advocates to New Obama EPA Director: We Look Forward to Toxic Chemical Regulatory Reform
9. Aon Appoints Environmental Veteran to Oversee Risk Management Services for Clients in Far East, Asia and Australia
10. Holland & Knight Welcomes MARC Associates - Experts in Health Care and Intergovernmental Policy - to the Firms Public Policy & Regulation Practice
11. Make a Mental Wellness New Years Resolution: How to Reduce Stress and Maintain Mental Health and Wellness in the Face of Economic Challenges
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CCHR Says New Mental Health Study on College Age Students Misleading
CCHR Says New Mental Health Study on College Age Students Misleading
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 1YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 3OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 1OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 2Fitness Might Limit Strokes Impact 51687 1Fitness Might Limit Strokes Impact 51687 2